Bio-Rad Laboratories (BIO-B) Other Non-Current Liabilities (2009 - 2026)

Bio-Rad Laboratories (BIO-B) has 18 years of Other Non-Current Liabilities data on file, last reported at $198.4 million in Q1 2026.

• Other Non-Current Liabilities for Q1 2026 came in at $198.4 million, up 14.62% year-over-year; the trailing twelve-month figure through Mar 2026 was $198.4 million (up 14.62% YoY), and the FY2025 annual result was $199.1 million, up 12.36% from the prior year.
• Other Non-Current Liabilities steadied at $198.4 million in Q1 2026 per BIO-B's latest filing, from $199.1 million in the prior quarter.
• Over five years, Other Non-Current Liabilities peaked at $209.6 million in Q2 2025 and troughed at $173.1 million in Q1 2025.
• A 5-year average of $193.5 million and a median of $195.9 million in 2022 frame the typical range for Other Non-Current Liabilities.
• The sharpest annual moves came in 2022 and 2026: Other Non-Current Liabilities dropped 21.31% in 2022, then increased 14.62% in 2026.
• A 5-year view of Other Non-Current Liabilities shows it stood at $195.9 million in 2022, then slipped by 0.47% to $195.0 million in 2023, then retreated by 9.13% to $177.2 million in 2024, then climbed by 12.36% to $199.1 million in 2025, then declined by 0.35% to $198.4 million in 2026.
• Business Quant data shows BIO-B's Other Non-Current Liabilities at $198.4 million in Q1 2026, $199.1 million in Q4 2025, and $207.5 million in Q3 2025.